BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., and Hedley Technologies (USA) Inc., a wholly owned subsidiary, operates the Companyâ€™s business marketing biologically and health-friendly non-chemical insecticides. The Companyâ€™s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn and Tibella, among others. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 is for the treatment of iron deficiency anemia. The Company also provides specialized healthcare products for dental hygiene and oral health.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	160M 113M 98.45M 91.07M 85M 10.65B 161M 1.08B 421M 5.23B 423M 414M 18.19B	P/E 2026 *	15.7x	P/E 2027 *	12.9x
Enterprise Value	160M 113M 98.45M 91.07M 85M 10.65B 161M 1.08B 421M 5.23B 423M 414M 18.19B	EV / Sales 2026 *	2.31x	EV / Sales 2027 *	1.94x
Free-Float	64.5%	Yield 2026 *	-	Yield 2027 *	-

05-22	BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026
05-19	BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution	MT
05-19	BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution)	CI
05-15	BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 15, 2025.	CI
05-14	BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026	CI
05-13	BioSyent Inc. Seeks Acquisitions	CI
03-24	BioSyent Inc., Q4 2025 Earnings Call, Mar 19, 2026
03-19	Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 16, 2024.	CI
03-19	Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 15, 2025.	CI
03-19	BioSyent Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-02	Biosyent announces closing of the acquisition of Oral Science Inc	RE
03-01	BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million.	CI

06-15	BioSyent to Present at Planet MicroCap Las Vegas	GL
05-19	BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)	GL
05-14	BioSyent : Financial Statements Q1 2026	PU
05-14	BioSyent : MDA Q1 2026	PU
05-14	BioSyent : Results Presentation Slides Q1 2026	PU

05-19	BioSyent annonce l’approbation de Thyconvi(MD) par Santé Canada (solution orale de lévothyroxine)
04-01	FeraMAX est le supplemént de fer le plus recommandé au Canada depuis 11 années consécutives
25-04-01	FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
24-04-03	FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives
23-08-08	BioSyent lance Inofolic® pour les femmes atteintes du syndrome des ovaires polykystiques (SOPK)

Manager	Title	Age	Since
René Goehrum CEO	Chief Executive Officer	66	1999-04-30
Robert March DFI	Director of Finance/CFO	-	2018-09-09
Navid Ashrafi CTO	Chief Tech/Sci/R&D Officer	-	2015-05-31

BioSyent Inc. Stock Other OTC

Stocks

BIOYF

CA0906901081

Pharmaceuticals

Valuation: BioSyent Inc.

Latest news : BioSyent Inc.

Last Transcript: BioSyent Inc.

Press Releases: BioSyent Inc.

News in other languages: BioSyent Inc.

Quotes and Performance

Managers and Directors: BioSyent Inc.

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
René Goehrum CHM	Chairman	66	1999-05-31
Peter Lockhard BRD	Director/Board Member	62	2002-05-31
Stephen Wilton BRD	Director/Board Member	65	2014-01-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYENT INC.	+0.67%	-.--%	-	-	113M
ELI LILLY AND COMPANY	+0.49%	-2.39%	+43.04%	+140.86%	980B
JOHNSON & JOHNSON	+1.00%	-2.20%	+52.31%	+39.16%	550B
ABBVIE INC.	+5.82%	+3.41%	+24.70%	+66.76%	382B
ROCHE HOLDING AG	-0.06%	-3.09%	+23.33%	+16.78%	316B
ASTRAZENECA PLC	+0.42%	+0.68%	+27.54%	+14.57%	272B
NOVARTIS AG	+1.67%	+0.05%	+26.50%	+33.56%	268B
NOVO NORDISK A/S	+2.39%	+5.02%	-33.44%	-44.76%	199B
AMGEN INC.	+1.62%	-2.26%	+25.76%	+49.19%	182B
GILEAD SCIENCES, INC.	+0.63%	-0.03%	+17.01%	+59.08%	154B
Average	+1.47%	-2.70%	+22.97%	+41.69%	366.93B
Weighted average by Cap.	+1.43%	-3.50%	+31.18%	+64.33%

	2026 *	2027 *
Net sales	69M 48.72M 42.57M 39.38M 36.76M 4.6B 69.51M 468M 182M 2.26B 183M 179M 7.86B	82.3M 58.11M 50.78M 46.97M 43.84M 5.49B 82.9M 558M 217M 2.7B 218M 213M 9.38B
Net income	-	-
Net Debt	-	-